Navigation Links
HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
Date:4/14/2008

nies. HUYA identifies and licenses the most promising pre-clinical and clinical stage compounds in China, leverages and extends the research efforts of its Chinese partners, and provides a bridge into the Western development process and biopharma market.

Because the compounds have already been validated through a rigorous discovery, selection and development process in China, this model streamlines and accelerates development in the West, while lowering risk. Moreover, the strength of HUYA's relationships with its Chinese partners ensures a continuous source of compounds for the future. This model contrasts with that of large pharmaceutical companies whose approach is to start their own research facilities in China, hoping to tap its large biotech talent pool, or that of smaller competitors with "one-off" single compound strategies.

About HUYA

HUYA is the leader in U.S./China pharmaceutical co-development. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and China. HUYA has joint headquarters offices in San Diego, CA, and Shanghai. Further information about the company is available at http://www.huyabio.com.

Contact:

USA: China:

Jan Tuttleman, Ph.D. Wen Chen, M.S., MBA

Vice President, Marketing Director of Business Development

HUYA Bioscience International, LLC HUYA Bioscience International

(858) 798-8800 86 (21) 51323312

jtuttleman@huyabio.com wchen@huyabio.com

Media Contacts:

Amy Berry
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
6. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
7. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
11. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... to find the best plan at the right price ... Through the end of the year, thousands of Nebraska ... health coverage. This is when the state,s 268,000 ... will sign up and pay for in 2010. ... this decision, says Independent Retail Pharmacist Steve Osenbaugh, of ...
(Date:12/15/2009)... CITY, Dec. 15 Dynatronics ... signed a preferred vendor agreement to provide therapy ... Inc. (PTP), a nationwide network of physical, occupational ... be working with Preferred Therapy Providers," said Larry ... marketing at Dynatronics. "Their vast network of 1,100 ...
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
Breaking Medicine Technology:Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 1Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 2Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 3Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 4Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 5Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 6Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 7Helix BioPharma Provides Updates on Topical Interferon Alpha 2b and L DOS47 Following Pre IND Meetings With the U S FDA 5263 8Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates 5260 1Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post stroke Upper Limb Spasticity 5258 1Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post stroke Upper Limb Spasticity 5258 2Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post stroke Upper Limb Spasticity 5258 3Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post stroke Upper Limb Spasticity 5258 4
... Use of in Vitro and Literature ... to Predict Effects of New HIV Therapies, MOUNTAIN VIEW, ... leading provider of software, strategic,consulting, and regulatory services for optimizing ... and,lead scientist, Strategic Consulting Services, has been invited to present,at ...
... Puroast(R) Low Acid Coffee,has conducted both chemistry and ... tasting, gourmet coffee provides symptom relief for those,with ... achieves,this without extractions, substitutes or additives; it uses ... Prior chemistry research at University of California, ...
Other Medicine Technology:Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 2Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 3Low Acid Coffee Backed By Scientific Research 2
(Date:12/15/2009)... to the Lupus Foundation of America and the Saint ... Julian Lennon, son of the legendary John ... digital single, "LUCY," to raise funds for research on ... 100 percent of the proceeds from downloading "LUCY" at ... America (LFA), and the Saint Thomas, Lupus Trust in ...
(Date:12/15/2009)... Vitech Systems Group, a leading provider of Benefits ... today that it has completed a major V3 ... Guild-Producers Pension & Health Plans (SAG-PH). ,, The ... SAG-PH call center personnel in Burbank, Ventura and ... V3 Benefits Administration System which consolidated data from ...
(Date:12/15/2009)... of leptin associated with lower dementia risk, research finds ... levels of leptin, a hormone that regulates appetite, may ... in 10 or 15 years this may be one ... risk of Alzheimer,s disease," said senior study author Dr. ... University School of Medicine. "Or it may be one ...
(Date:12/15/2009)... needed for protection, CDC says, , , TUESDAY, Dec. 15 ... swine flu vaccine have been recalled by manufacturer Sanofi ... health officials said Tuesday. , According to the U.S. ... testing of the vaccine for children aged 6 months ... lower than required potency levels. "This means that doses ...
(Date:12/15/2009)... tests promised but not delivered ,, WASHINGTON, ... on Congress to ensure that healthcare reform does ... required of insurance companies in 37 states. ,, ... segments of the population and individuals who are ... and men who have a family history of ...
Breaking Medicine News(10 mins):Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... estrogen replacement proved more dangerous , , MONDAY, April 7 (HealthDay ... and risks of hormone therapy for women, a new study ... determine whether it helps or harms her. , The study, ... safer, while moderate and high doses increased the risk of ...
... use of robotics for minimally invasive cardiac surgery. He ... surgery. With his arrival, BMC has become one of ... only hospital in Boston, to offer robot-assisted minimally invasive coronary ... disease (the most common form of heart disease - 16 ...
... York Hospital Upgrades Three X-Ray Rooms from Film to IDC Digital ... ... 7 /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global ... Saratoga Hospital in Saratoga,Springs, New York has purchased IDC,s X2200, X1590, ...
... April 7, 2008 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... a,conference call and live webcast at 8:30 am (EDT) ... will be to discuss the Company,s April 7, 2008,meeting ... the planned NDA,submission for the Company,s novel once-a-day oral ...
... developed algorithm has significantly advanced understanding of the ... brain tumor in adults, human glioblastoma (GBM). The ... issue of the journal Cancer Cell, validates known ... with GBM, thereby elucidating new directions for potential ...
... BOSTON--The search for cancer genes is increasingly a matter ... to distinguish genes actually involved in the disease from ... hundreds or thousands of genetic irregularities in tumor tissue, ... true culprits. , In a new study in the ...
Other Medicine News:Health News:HRT Dosing May Determine Risks, Benefits 2Health News:HRT Dosing May Determine Risks, Benefits 3Health News:Robot-assisted minimally-invasive CABG surgery 2Health News:Saratoga Hospital Purchases Three IDC DR Systems 2Health News:Saratoga Hospital Purchases Three IDC DR Systems 3Health News:Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA 2Health News:Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA 3Health News:New regulatory circuit identified for aggressive, malignant brain tumor 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 2Health News:Data-handling technique finds genes to be team players in curbing brain cancer cell growth 3
... designed for use with our CARTO EP ... catheter houses a Biosense Webster sensor at ... time, exact location points from within the ... The NAVI-STAR electro-anatomical navigation catheter is used ...
... catheter incorporates six electrodes which are spaced ... single catheter. Positioned in the Right Atrium, ... atrial electrograms. The catheter may then be ... atrial recording and ventricular pacing and recording. ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
... Soloist Quadripolar Multilumen Shaft ... The Medtronic ... intended for use in ... catheter is designed for ...
Medicine Products: